NCT05561530

A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

A Phase 1/1b, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Subcutaneously Administered ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Ascending Doses in Healthy Volunteers (Part 1) and Subjects With Chronic Hepatitis B (Part 2), and Multiple Doses in Subjects With Chronic Hepatitis B (Part 3)

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Aligos Therapeutics · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

A randomized study of ALG-125755 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics after single doses in healthy volunteers, and single and multiple doses in CHB subjects

Conditions

• Chronic Hepatitis B

Interventions

Type	Name	Description
DRUG	ALG-125755	single or multiple doses of ALG-125755
DRUG	Placebo	single or multiple doses of placebo

Timeline

• Start date: 2022-10-07
• Primary completion: 2023-06-15
• Completion: 2023-06-15
• First posted: 2022-09-30
• Last updated: 2024-03-15

Locations

4 sites across 4 countries: Bulgaria, Moldova, New Zealand, Romania